RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Inclusion criteria

• ✓. voluntarily agree to participate in the study and sign an informed consent form;
• ✓. male or female, age ≥18 years;
• ✓. disease fulfillment:
• ✓. the patient's disease status was determined by at least two associate or chief physicians to be free of visible lesions to the naked eye after transurethral bladder tumor electrodessication;
• ✓. A definitive postoperative pathologic diagnosis of non-muscle invasive bladder cancer with \>50% of its major tissue component being uroepithelial carcinoma (migratory cell carcinoma);
• ✓. Completion of TURBT within 4 weeks prior to study administration and completion of immediate chemotherapy infusion (chemotherapy agent is mitomycin);
• ✓. Absence of focal lymph node metastasis as well as distant metastasis confirmed by imaging (including but not limited to thoracoabdominopelvic CT/MR or PET/CT) within 6 weeks prior to enrollment, i.e., N0M0;
• ✓. Subject's NMIBC risk grouping is consistent with a high or very high risk group:

Exclusion criteria